Literature DB >> 17011767

The role of SAP and the SLAM family in autoimmunity.

Alice Y Chan1, Jill M Westcott, Jill M Mooney, Edward K Wakeland, John D Schatzle.   

Abstract

The signaling lymphocyte activation molecule (SLAM) family of receptors and their associated signaling adaptors play a pivotal role in the regulation of various stages of cellular immunity. They regulate lymphocyte-lymphocyte interactions involved in both cell-mediated and humoral immune responses. Recent evidence indicates that members of this family of receptors and signaling intermediates are also involved in autoimmunity. These include strictly correlative studies showing increased expression of various family members in immune effectors involved in rheumatoid arthritis and in inflammatory bowel disease, as well as more direct evidence (from various knockout strains of mice) for their role in autoimmune processes such as experimental allergic encephalomyelitis and lupus. Additional studies defining naturally occurring polymorphic variations in the SLAM family show a direct role in initiating the break in tolerance that is an essential step in the progression towards autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17011767     DOI: 10.1016/j.coi.2006.09.010

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  16 in total

1.  Germinal center T follicular helper cell IL-4 production is dependent on signaling lymphocytic activation molecule receptor (CD150).

Authors:  Isharat Yusuf; Robin Kageyama; Laurel Monticelli; Robert J Johnston; Daniel Ditoro; Kyle Hansen; Burton Barnett; Shane Crotty
Journal:  J Immunol       Date:  2010-06-04       Impact factor: 5.422

2.  Invariant NKT cell development requires a full complement of functional CD3 zeta immunoreceptor tyrosine-based activation motifs.

Authors:  Amy M Becker; Jon S Blevins; Farol L Tomson; Jennifer L Eitson; Jennifer J Medeiros; Felix Yarovinsky; Michael V Norgard; Nicolai S C van Oers
Journal:  J Immunol       Date:  2010-05-14       Impact factor: 5.422

3.  SAP and Lessons Learned from a Primary Immunodeficiency.

Authors:  Jennifer L Cannons; Pamela L Schwartzberg
Journal:  J Immunol       Date:  2017-09-01       Impact factor: 5.422

4.  Latent membrane protein 1, the EBV-encoded oncogenic mimic of CD40, accelerates autoimmunity in B6.Sle1 mice.

Authors:  Anna L Peters; Laura L Stunz; David K Meyerholz; Chandra Mohan; Gail A Bishop
Journal:  J Immunol       Date:  2010-09-01       Impact factor: 5.422

5.  Optimal germinal center responses require a multistage T cell:B cell adhesion process involving integrins, SLAM-associated protein, and CD84.

Authors:  Jennifer L Cannons; Hai Qi; Kristina T Lu; Mala Dutta; Julio Gomez-Rodriguez; Jun Cheng; Edward K Wakeland; Ronald N Germain; Pamela L Schwartzberg
Journal:  Immunity       Date:  2010-02-11       Impact factor: 31.745

6.  Analysis of the cellular mechanism underlying inhibition of EAE after treatment with anti-NKG2A F(ab')2.

Authors:  Jianmei W Leavenworth; Carola Schellack; Hye-Jung Kim; Linrong Lu; Pieter Spee; Harvey Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-21       Impact factor: 11.205

Review 7.  SLAM receptors and SAP influence lymphocyte interactions, development and function.

Authors:  Pamela L Schwartzberg; Kristen L Mueller; Hai Qi; Jennifer L Cannons
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

8.  High expression of CD244 and SAP regulated CD8 T cell responses of patients with HTLV-I associated neurologic disease.

Authors:  Yoshimi Enose-Akahata; Eiji Matsuura; Unsong Oh; Steven Jacobson
Journal:  PLoS Pathog       Date:  2009-12-04       Impact factor: 6.823

Review 9.  Innate receptors and microbes in induction of autoimmunity.

Authors:  Alexander Chervonsky
Journal:  Curr Opin Immunol       Date:  2009-09-09       Impact factor: 7.486

10.  Ly9 (CD229) Cell-Surface Receptor is Crucial for the Development of Spontaneous Autoantibody Production to Nuclear Antigens.

Authors:  Jose de Salort; Marta Cuenca; Cox Terhorst; Pablo Engel; Xavier Romero
Journal:  Front Immunol       Date:  2013-07-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.